- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | Psyence Biomedical expands Australian clinical sites to five | 2 | Investing.com | ||
| 08.04. | Psyence Biomedical baut Studiennetzwerk in Australien aus | 2 | Investing.com Deutsch | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 08.04. | Psyence Biomedical Ltd.: Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5-Supported Clinical Activities | 1 | GlobeNewswire (USA) | ||
| 11.03. | Psyence Biomedical Ltd.: Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone | 1 | GlobeNewswire (USA) | ||
| 03.03. | Psyence Biomedical Ltd.: Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial | 295 | GlobeNewswire (Europe) | NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 02.03. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.02. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment | 393 | GlobeNewswire (Europe) | NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 17.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders | 196 | GlobeNewswire (Europe) | NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 14.02. | Psyence Biomedical Ltd.: Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway | 429 | GlobeNewswire (Europe) | NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 12.02. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.02. | Psyence Biomedical-Aktie fällt nach Beilegung von Aktionärsstreit | 1 | Investing.com Deutsch | ||
| 11.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Settlement of Shareholder Litigation | 401 | GlobeNewswire (Europe) | NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direct... ► Artikel lesen | |
| 03.02. | Morning Market Movers: FatPipe, FiEE, Teradyne, Psyence Biomedical, See Big Swings | 559 | AFX News | OTTAWA (dpa-AFX) - At 6:44 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 29.01. | Psyence Biomedical announces 1-for-6.25 share consolidation | 2 | Investing.com | ||
| 29.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split | 130 | GlobeNewswire (Europe) | NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), today announced the effective date of its 1-for-6.25 share consolidation (reverse... ► Artikel lesen | |
| 27.01. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026 | 2 | GlobeNewswire (USA) | ||
| 20.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date | 214 | GlobeNewswire (Europe) | NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), today announced that it has decided to postpone the previously announced effective... ► Artikel lesen | |
| 15.01. | Psyence Biomedical sets Jan. 20 as effective date for reverse stock split | 1 | Seeking Alpha |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 1,770 | 0,00 % | BioLineRx Ltd.: BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers
GLIX1 has demonstrated potent... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 8,910 | 0,00 % | Transcode Therapeutics, Inc. - 10-K, Annual Report | ||
| MINK THERAPEUTICS | 11,200 | 0,00 % | MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum | ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000-300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing... ► Artikel lesen | |
| SILEXION THERAPEUTICS | 1,030 | 0,00 % | Silexion Therapeutics Corp: Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting... ► Artikel lesen | |
| QIAGEN | 35,000 | -1,71 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| EVOTEC | 5,570 | +0,54 % | Mutares: Exklusiv-Interview - Deutz, Elmos, Evotec, Infineon und Rheinmetall - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BIONTECH | 86,40 | +2,49 % | BioNTech-Aktie: Wann geht's wieder über 100 Euro? | BioNTech hat neue klinische Daten zu einem wichtigen Krebsmedikament veröffentlicht und damit erneut Fortschritte in seiner Onkologie-Pipeline demonstriert. Für Investoren sind solche Studiendaten entscheidend... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,610 | +11,90 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,735 | -0,40 % | Recursion-CEO erläutert KI-Strategie zur Beschleunigung der Medikamentenentwicklung | ||
| GENMAB | 237,90 | -4,23 % | Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) on Tuesday reported global net trade sales of $3.964 billion for DARZALEX (daratumumab) in the first quarter of 2026, according to company announcements.... ► Artikel lesen | |
| VALNEVA | 2,599 | -2,07 % | Guggenheim senkt Kursziel für Valneva-Aktie wegen Lyme-Impfstoff auf 11 US-Dollar | ||
| ALLOGENE THERAPEUTICS | 2,335 | +7,85 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,630 | -0,09 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| PRAXIS PRECISION MEDICINES | 317,82 | -6,45 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,120 | -1,81 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
PSYENCE BIOMEDICAL LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +4,270 (+149,82 %) liegt der Kurs bei 7,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.